6430706D22Rik Inhibitors
Chemical inhibitors of protein 6430706D22Rik can be utilized to modulate its function through the selective blockade of specific signaling pathways that govern its activity. LY294002 and Wortmannin, for example, can directly inhibit the phosphatidylinositol 3-kinase (PI3K) enzyme, which is a precursor in the PI3K/AKT pathway that 6430706D22Rik is a part of. By preventing PI3K from activating AKT, these inhibitors can decrease the activity of 6430706D22Rik if its function is downstream of AKT. Rapamycin serves a similar purpose but targets the pathway further downstream by inhibiting the mammalian target of rapamycin (mTOR), which can suppress the signaling that might influence 6430706D22Rik's function.
In addition to the PI3K/AKT/mTOR pathway, the MAPK/ERK pathway is another route by which the function of 6430706D22Rik can be influenced. PD98059 and U0126 are both inhibitors of MEK, which is upstream of ERK in the MAPK/ERK pathway. By preventing MEK from initiating the phosphorylation of ERK, they can control the activity levels of 6430706D22Rik if it is regulated by this particular pathway. SB203580 and SP600125 target different arms of the MAP kinase pathways-p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively-offering alternative avenues for controlling 6430706D22Rik activity. Similarly, the Src family kinases, which can be inhibited by PP2, are involved in a variety of signaling cascades, and their inhibition can affect the functional state of 6430706D22Rik. Bisindolylmaleimide I and GF 109203X, both specific inhibitors of protein kinase C (PKC), can modulate the activity of 6430706D22Rik by targeting PKC-dependent signaling processes. Finally, ZM 336372 and SL 327 focus on inhibiting RAF and MEK respectively, which are critical components of the MAPK/ERK pathway, and their inhibition can alter the signaling cascade that may affect 6430706D22Rik function. Through these diverse chemical inhibitors, the activity of protein 6430706D22Rik can be modulated by targeting different kinases and pathways that control its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K), which can inhibit the PI3K/AKT pathway. Since 6430706D22Rik is involved in this pathway, the inhibition of PI3K can lead to a decrease in AKT activation, thereby functionally inhibiting 6430706D22Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the enzyme, which is upstream of AKT. Inhibition of PI3K by Wortmannin would decrease AKT phosphorylation, thus functionally inhibiting 6430706D22Rik if it acts downstream of AKT. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a key kinase in the PI3K/AKT/mTOR pathway. Inhibition of mTOR by Rapamycin can suppress downstream signaling, ultimately leading to functional inhibition of 6430706D22Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK, possibly leading to functional inhibition of 6430706D22Rik if it is involved in this signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of downstream kinases in the MAPK/ERK pathway. By inhibiting MEK, U0126 can functionally inhibit 6430706D22Rik if it is part of the pathway or is regulated by it. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in the response to stress and cytokines. If 6430706D22Rik operates within this pathway, inhibition of p38 MAP kinase could lead to functional inhibition of 6430706D22Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), affecting the JNK signaling pathway. The inhibition of JNK can lead to functional inhibition of 6430706D22Rik if JNK signaling regulates this protein's activity. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $84.00 $142.00 | 6 | |
PP2 is a selective inhibitor of Src family kinases. Inhibition of these kinases can disrupt multiple signaling pathways, leading to functional inhibition of 6430706D22Rik if it is regulated by Src family kinase activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). By inhibiting PKC, this compound can functionally inhibit 6430706D22Rik if PKC is involved in its regulation or if 6430706D22Rik is part of a PKC-dependent signaling pathway. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM 336372 is a potent inhibitor of RAF kinases, which play a role in the MAPK/ERK signaling pathway. By inhibiting RAF, this chemical can inhibit downstream signaling, potentially leading to functional inhibition of 6430706D22Rik if it is part of this pathway. | ||||||